- Home
- NMIH vs MLYS Comparison
NMIH vs MLYS Comparison
Compare NMIH & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMIH
- MLYS
- Stock Information
- Founded
- NMIH 2011
- MLYS 2019
- Country
- NMIH United States
- MLYS United States
- Employees
- NMIH N/A
- MLYS N/A
- Industry
- NMIH Property-Casualty Insurers
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- NMIH Finance
- MLYS Health Care
- Exchange
- NMIH Nasdaq
- MLYS Nasdaq
- Market Cap
- NMIH 2.9B
- MLYS 3.1B
- IPO Year
- NMIH 2013
- MLYS 2023
- Fundamental
- Price
- NMIH $35.84
- MLYS $43.63
- Analyst Decision
- NMIH Buy
- MLYS Strong Buy
- Analyst Count
- NMIH 6
- MLYS 6
- Target Price
- NMIH $42.33
- MLYS $42.60
- AVG Volume (30 Days)
- NMIH 369.6K
- MLYS 1.4M
- Earning Date
- NMIH 11-04-2025
- MLYS 11-10-2025
- Dividend Yield
- NMIH N/A
- MLYS N/A
- EPS Growth
- NMIH 11.30
- MLYS N/A
- EPS
- NMIH 4.71
- MLYS N/A
- Revenue
- NMIH $679,621,000.00
- MLYS N/A
- Revenue This Year
- NMIH N/A
- MLYS N/A
- Revenue Next Year
- NMIH $5.15
- MLYS N/A
- P/E Ratio
- NMIH $7.60
- MLYS N/A
- Revenue Growth
- NMIH 9.99
- MLYS N/A
- 52 Week Low
- NMIH $31.90
- MLYS $8.24
- 52 Week High
- NMIH $43.20
- MLYS $44.80
- Technical
- Relative Strength Index (RSI)
- NMIH 35.08
- MLYS 71.05
- Support Level
- NMIH $35.11
- MLYS $37.54
- Resistance Level
- NMIH $36.52
- MLYS $44.80
- Average True Range (ATR)
- NMIH 0.66
- MLYS 2.36
- MACD
- NMIH -0.10
- MLYS -0.34
- Stochastic Oscillator
- NMIH 17.21
- MLYS 83.55
About NMIH NMI Holdings Inc.
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.